当前期刊: Journal of Clinical Oncology Go to current issue    加入关注   
显示样式:        排序: IF: - GO 导出
我的关注
我的收藏
您暂时未登录!
登录
  • Molecular Risk Stratification in Aggressive B-Cell Lymphomas
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-02
    Zachary A.K. Frosch; Daniel J. Landsburg

    In recent years, it has become increasingly apparent that diffuse large B-cell lymphoma (DLBCL) is not a single pathologic entity. Widely available diagnostic techniques such as immunohistochemical staining and fluorescence in situ hybridization (FISH) have helped to subcategorize DLBCLs by their pathologic features and identify those associated with a lower probability of cure after standard first-line

    更新日期:2020-04-03
  • Food Is Love: Partnering With Families to Provide Nourishment at the End of Life
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-02
    Erica C. Kaye; Anna Kegel; Madeline Weber; Carla Cartwright; Holly Spraker-Perlman; Giles W. Robinson; Justin N. Baker

    Alonso was a 10-year-old boy with a recurrent, refractory brain tumor whose disease progressed through multiple therapies over many years. When no additional cancer-directed options remained, Alonso was admitted to the hospital for symptom management as he approached the end of his life. Although Alonso was unresponsive and posturing, his family continued to hope desperately for a miracle. As they

    更新日期:2020-04-03
  • Systemic Therapy for Melanoma: ASCO Guideline
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-31
    Rahul Seth; Hans Messersmith; Varinder Kaur; John M. Kirkwood; Ragini Kudchadkar; Jennifer Leigh McQuade; Anthony Provenzano; Umang Swami; Jeffrey Weber; Krishna C. Alluri; Sanjiv Agarwala; Paolo A. Ascierto; Michael B. Atkins; Nancy Davis; Marc S. Ernstoff; Mark B. Faries; Jason S. Gold; Samantha Guild; David E. Gyorki; Nikhil I. Khushalani; Michael O. Meyers; Caroline Robert; Mario Santinami; Amikar

    PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for melanoma.METHODS ASCO convened an Expert Panel and conducted a systematic review of the literature.RESULTS A systematic review, one meta-analysis, and 34 additional randomized trials were identified. The published studies included a wide range of systemic therapies in cutaneous and noncutaneous melanoma.RECOMMENDATIONS

    更新日期:2020-04-01
  • Novel Insights Into the Long-Term Immune Health of Diffuse Large B-Cell Lymphoma Survivors
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-31
    Lindsay M. Morton

    Introduction of the anti-CD20 monoclonal antibody rituximab in 1997 substantially improved prognosis after a diagnosis of diffuse large B-cell lymphoma (DLBCL),1 which affects > 27,000 individuals in the United States annually.2 With the 5-year relative survival increasing from 43% in the early 1990s to > 65% since 2010 (Fig 1),3 attention has increasingly turned toward improving understanding of patients’

    更新日期:2020-04-01
  • Neurocognitive Outcomes for Patients With Brain Metastasis in the Modern Era: Benefit of Treatment With Hippocampal Avoidance Whole-Brain Radiotherapy Plus Memantine.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01
    Joseph P Weiner

    Whole-brain radiotherapy (WBRT) has been the cornerstone treatment of patients with multiple brain metastases since its introduction in the 1950s.1 Today, it remains one of the most commonly delivered oncologic treatments, with > 200,000 patients per year receiving this treatment in the United States.2 Historically, the prognosis for these patients was generally poor, with survival measured in weeks

    更新日期:2020-03-28
  • Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01
    Kim-Hien T Dao,Jason Gotlib,Michael M N Deininger,Stephen T Oh,Jorge E Cortes,Robert H Collins,Elliot F Winton,Dana R Parker,Hyunjung Lee,Anna Reister,Schultz,Samantha Savage,Stevens,Chase Brockett,Nan Subbiah,Richard D Press,Philipp W Raess,Michael Cascio,Jennifer Dunlap,Yiyi Chen,Catherine Degnin,Julia E Maxson,Cristina E Tognon,Tara Macey,Brian J Druker,Jeffrey W Tyner

    PURPOSE Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling. We sought to evaluate safety and efficacy of the JAK1/2 inhibitor ruxolitinib in patients with CNL and aCML, irrespective of CSF3R mutation status. METHODS

    更新日期:2020-03-28
  • Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01
    Paul D Brown,Vinai Gondi,Stephanie Pugh,Wolfgang A Tome,Jeffrey S Wefel,Terri S Armstrong,Joseph A Bovi,Cliff Robinson,Andre Konski,Deepak Khuntia,David Grosshans,Tammie L S Benzinger,Deborah Bruner,Mark R Gilbert,David Roberge,Vijayananda Kundapur,Kiran Devisetty,Sunjay Shah,Kenneth Usuki,Bethany Marie Anderson,Baldassarre Stea,Harold Yoon,Jing Li,Nadia N Laack,Tim J Kruser,Steven J Chmura,Wenyin

    PURPOSE Radiation dose to the neuroregenerative zone of the hippocampus has been found to be associated with cognitive toxicity. Hippocampal avoidance (HA) using intensity-modulated radiotherapy during whole-brain radiotherapy (WBRT) is hypothesized to preserve cognition. METHODS This phase III trial enrolled adult patients with brain metastases to HA-WBRT plus memantine or WBRT plus memantine. The

    更新日期:2020-03-28
  • EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01
    Jonathan Rosenberg,Srikala S Sridhar,Jingsong Zhang,David Smith,Dean Ruether,Thomas W Flaig,Joaquina Baranda,Joshua Lang,Elizabeth R Plimack,Randeep Sangha,Elisabeth I Heath,Jamie Merchan,David I Quinn,Sandy Srinivas,Matthew Milowsky,Chunzhang Wu,Elaina M Gartner,Peiying Zuo,Amal Melhem-Bertrandt,Daniel P Petrylak

    PURPOSE To assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV), a novel investigational antibody-drug conjugate that delivers the microtubule-disrupting agent, monomethyl auristatin E, to cells that express Nectin-4. METHODS EV-101 is a phase I dose escalation/expansion study that enrolled patients with Nectin-4-expressing solid tumors (eg, metastatic urothelial carcinoma

    更新日期:2020-03-28
  • Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01
    Shitanshu Uppal,Paola A Gehrig,Katherine Peng,Kristin L Bixel,Koji Matsuo,Monica H Vetter,Brittany A Davidson,M Paige Cisa,Brittany F Lees,Laurie L Brunette,Katherine Tucker,Allison Stuart Staley,Walter H Gotlieb,Robert W Holloway,Kathleen G Essel,Laura L Holman,Ester Goldfeld,Alexander Olawaiye,Stephen L Rose

    PURPOSE To compare the disease-free survival (DFS) between open and minimally invasive radical hysterectomies (RH) performed in academic medical institutions. METHODS Retrospective multi-institutional review of patients undergoing RH for stage IA1 (with lymphovascular invasion), IA2, and IB1 squamous, adenocarcinoma, or adenosquamous carcinoma between January 1, 2010 and December 31, 2017. RESULTS

    更新日期:2020-03-28
  • Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01
    Bhishamjit S Chera,Sunil Kumar,Colette Shen,Robert Amdur,Roi Dagan,Rebecca Green,Emily Goldman,Jared Weiss,Juneko Grilley-Olson,Shetal Patel,Adam Zanation,Trevor Hackman,Jeff Blumberg,Samip Patel,Brian Thorp,Mark Weissler,Wendell Yarbrough,Nathan Sheets,William Mendenhall,Xianming M Tan,Gaorav P Gupta

    PURPOSE Plasma circulating tumor human papillomavirus DNA (ctHPVDNA) is a sensitive and specific biomarker of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). We investigated whether longitudinal monitoring of ctHPVDNA during post-treatment surveillance could accurately detect clinical disease recurrence. METHODS AND MATERIALS A prospective biomarker clinical trial

    更新日期:2020-03-28
  • MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01
    A Jo Chien,Debasish Tripathy,Kathy S Albain,W Fraser Symmans,Hope S Rugo,Michelle E Melisko,Anne M Wallace,Richard Schwab,Teresa Helsten,Andres Forero-Torres,Erica Stringer-Reasor,Erin D Ellis,Henry G Kaplan,Rita Nanda,Nora Jaskowiak,Rashmi Murthy,Constantine Godellas,Judy C Boughey,Anthony D Elias,Barbara B Haley,Kathleen Kemmer,Claudine Isaacs,Amy S Clark,Julie E Lang,Janice Lu,Larissa Korde,Kirsten

    PURPOSE The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survival and therapeutic resistance in breast cancer. We evaluated the pan-Akt inhibitor MK-2206 in combination with standard therapy in patients with high-risk early-stage breast cancer. PATIENTS AND METHODS I-SPY 2 is a multicenter, phase II, open-label, adaptively randomized neoadjuvant platform trial

    更新日期:2020-03-28
  • Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01
    Justin Stebbing,Paul N Mainwaring,Giuseppe Curigliano,Mark Pegram,Mark Latymer,Angel H Bair,Hope S Rugo

    Biosimilars have the potential to broaden patient access to biologics and provide cost savings for health care systems. During the development of a biosimilar, data that directly compare the proposed biosimilar with the reference product are required. Such comparative data are generated in a stepwise hierarchical process that begins with extensive laboratory-based structural analyses and functional

    更新日期:2020-03-28
  • Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01
    Merry Jennifer Markham,Kerri Wachter,Neeraj Agarwal,Monica M Bertagnolli,Susan Marina Chang,William Dale,Catherine S M Diefenbach,Carlos Rodriguez-Galindo,Daniel J George,Timothy D Gilligan,R Donald Harvey,Melissa L Johnson,Randall J Kimple,Miriam A Knoll,Noelle LoConte,Robert G Maki,Jane Lowe Meisel,Jeffrey A Meyerhardt,Nathan A Pennell,Gabrielle B Rocque,Michael S Sabel,Richard L Schilsky,Bryan James

    Shortly before I was elected President of ASCO, I attended the 65th birthday party of a current patient. She had been diagnosed 10 years earlier with metastatic breast cancer and hadn't been sure she wanted to move forward with further treatment. With encouragement, she elected to participate in a clinical trial of an investigational drug that is now widely used to treat breast cancer. Happily, here

    更新日期:2020-03-28
  • Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01
    Elaine S Jaffe,Binita S Ashar,Mark W Clemens,Andrew L Feldman,Philippe Gaulard,Roberto N Miranda,Aliyah R Sohani,Timothy Stenzel,Sung W Yoon

    PURPOSE To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulectomy specimen. METHODS To better inform patients and healthcare providers about BIA-ALCL, we convened to review diagnostic procedures used in the evaluation

    更新日期:2020-03-28
  • The Median Isn't the Message: Revisited.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01
    Stanley I Gutiontov

    As soon as Mary opened her mouth, it was clear something was wrong. “I . . . hard . . . can’t . . . .” Her forehead creased in spite of her broad smile. She wrung her hands together and looked earnestly at me. “Not . . . .”

    更新日期:2020-03-28
  • Inability of Fluorodeoxyglucose Positron Emission Tomography to Detect Viable Hodgkin Lymphoma During and After Treatment.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01
    Hugo J A Adams,Thomas C Kwee

    The HD16 trial described by Fuchs et al1 aimed to determine whether fluorodeoxyglucose positron emission tomography (FDG-PET) scans after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) might help predict individual outcomes and guide treatment. Of the 1,007 patients included, FDG-PET after 2 cycles of ABVD revealed a Deauville score (DS) of 1 or 2 in 667 patients (66%), a DS

    更新日期:2020-03-28
  • Reply to H.J.A. Adams et al.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01
    Michael Fuchs,Helen Goergen,Carsten Kobe,Peter Borchmann,Andreas Engert

    We thank Adams and Kwee1 for their interest in our HD16 trial2 and their comments. The study in patients with early-stage favorable Hodgkin lymphoma (HL) was designed to clarify whether additional involved-field radiotherapy of 20 Gy can be omitted in patients with a negative fluorodeoxyglucose (FDG) positron emission tomography (PET) scan after 2 cycles of doxorubicin, bleomycin, vinblastine, and

    更新日期:2020-03-28
  • Errata
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01

    The August 20, 2018, article by Klopp et al entitled “Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology–RTOG 1203” (J Clin Oncol 10.1200/JCO.2017.77.4273) was published with errors.

    更新日期:2020-03-28
  • Errata
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-04-01

    The August 1, 2019, article by Ma et al entitled “Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus–Associated Oropharynx Squamous Cell Carcinoma” (J Clin Oncol 10.1200/JCO.19.00463) was published with an error.

    更新日期:2020-03-28
  • First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-26
    Raffit Hassan; George R. Blumenschein Jr; Kathleen N. Moore; Alessandro D. Santin; Hedy L. Kindler; John J. Nemunaitis; Shelly M. Seward; Anish Thomas; Stella K. Kim; Prabhu Rajagopalan; Annette O. Walter; Dirk Laurent; Barrett H. Childs; Nenad Sarapa; Cem Elbi; Johanna C. Bendell

    PURPOSE This phase I study, which to our knowledge is the first-in-human study of this kind, investigates the safety, tolerability, pharmacokinetics, and clinical activity of anetumab ravtansine, an antibody–drug conjugate of anti-mesothelin antibody linked to maytansinoid DM4, in patients with advanced, metastatic, or recurrent solid tumors known to express the tumor-differentiation antigen mesothelin

    更新日期:2020-03-27
  • Status Update on Data Required to Build a Learning Health System
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-25
    Monica M. Bertagnolli; Brian Anderson; Kelly Norsworthy; Steven Piantadosi; Andre Quina; Richard L. Schilsky; Robert S. Miller; Sean Khozin

    Wide adoption of electronic health records (EHRs) has raised the expectation that data obtained during routine clinical care, termed “real-world” data, will be accumulated across health care systems and analyzed on a large scale to produce improvements in patient outcomes and the use of health care resources. To facilitate a learning health system, EHRs must contain clinically meaningful structured

    更新日期:2020-03-26
  • Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-25
    Pirus Ghadjar; Dirk Böhmer; Stefan Höcht; Felix Sedlmayer; Thomas Wiegel

    Malone et al1 performed a randomized trial comparing 6 months of neoadjuvant versus adjuvant androgen deprivation therapy (ADT) combined with dose-escalated radiation therapy (RT) in 432 patients with localized prostate cancer, with the primary end point being biochemical recurrence-free survival (bRFS). For RT, 76 Gy (prostate only) in 38 fractions was applied using image-guided three-dimensional

    更新日期:2020-03-26
  • Reply to P. Ghadjar et al
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-25
    Soumyajit Roy; Shawn Malone

    The National Comprehensive Cancer Network (NCCN) risk-stratification system, categorizing intermediate-risk prostate cancer (PCa) into favorable and unfavorable subgroups, has unveiled better opportunities to personalize treatment in men with intermediate-risk PCa.1 ASCO, the American Urological Association, and the American Society for Radiation Oncology guidelines do not provide any specific recommendation

    更新日期:2020-03-26
  • Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-24
    William D. Tap; Victor M. Villalobos; Gregory M. Cote; Howard Burris; Filip Janku; Olivier Mir; Murali Beeram; Andrew J. Wagner; Liewen Jiang; Bin Wu; Sung Choe; Katharine Yen; Camelia Gliser; Bin Fan; Sam Agresta; Shuchi S. Pandya; Jonathan C. Trent

    PURPOSE Surgery is the primary therapy for localized chondrosarcoma; for locally advanced and/or metastatic disease, no known effective systemic therapy exists. Mutations in the isocitrate dehydrogenase 1/2 (IDH1/2) enzymes occur in up to 65% of chondrosarcomas, resulting in accumulation of the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (AG-120) is a selective inhibitor of mutant IDH1 approved

    更新日期:2020-03-26
  • Increased Risk of Multiple Spontaneous Vertebral Fractures at Denosumab Discontinuation Must Be Taken Into Account
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-24
    Elena Gonzalez-Rodriguez; Bérengère Aubry-Rozier; Delphine Stoll; Khalil Zaman; Olivier Lamy

    We read with great interest in Journal of Clinical Oncology the ASCO Clinical Practice Guideline by Shapiro et al1 on the management of osteoporosis in survivors of adult cancers with nonmetastatic disease. We are concerned by the limited information given about the risk of multiple spontaneous vertebral fractures (MSVFs) at denosumab discontinuation. The recommendations and the discussion should address

    更新日期:2020-03-26
  • Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-24
    Jennifer L. Beebe-Dimmer; Ashley L. Kapron; Alison M. Fraser; Ken R. Smith; Kathleen A. Cooney

    PURPOSE Recently developed clinical guidelines suggest that men in families with specific cancer syndromes, such as hereditary breast and ovarian cancer (HBOC), consider genetic testing, especially in the setting of aggressive disease. However, although a family history (FH) of the same disease among close relatives is an established risk factor for prostate cancer (PC), a direct comparison of PC risk

    更新日期:2020-03-26
  • Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-24
    Akitaka Makiyama; Yasutaka Sukawa; Tomomi Kashiwada; Junji Kawada; Ayumu Hosokawa; Yoshiki Horie; Akihito Tsuji; Toshikazu Moriwaki; Hiroaki Tanioka; Katsunori Shinozaki; Keita Uchino; Hirofumi Yasui; Hiroshi Tsukuda; Kazuhiro Nishikawa; Hiroyasu Ishida; Takeharu Yamanaka; Kentaro Yamazaki; Shuichi Hironaka; Taito Esaki; Narikazu Boku; Ichinosuke Hyodo; Kei Muro

    PURPOSE This study evaluated the continuous use of trastuzumab beyond progression (TBP) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (G/GEJ) cancer.PATIENTS AND METHODS Patients with HER2-positive advanced G/GEJ cancer refractory to first-line chemotherapy with trastuzumab in combination with fluoropyrimidine and platinum were eligible. Patients

    更新日期:2020-03-26
  • Reply to E. Gonzalez-Rodriguez et al
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-24
    Charles L. Shapiro; Christina Lacchetti; Joan Neuner

    We thank Gonzalez-Rodriguez et al1 for pointing out the important risks of multiple spontaneous (atraumatic) vertebral fractures (MSVFs) that are due to denosumab discontinuation. Because of risks of MSVF, they disagree with recommendation 3.4 in the ASCO Clinical Practice Guideline regarding the use of oral and intravenous bisphosphonates or denosumab as treatment options for individuals with nonmetastatic

    更新日期:2020-03-26
  • Risk Factors for Small Adult Height in Childhood Cancer Survivors
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-20
    Charlotte Demoor-Goldschmidt; Rodrigue S. Allodji; Neige Journy; Carole Rubino; Wael Salem Zrafi; Ghazi Debiche; Damien Llanas; Cristina Veres; Cécile Thomas-Teinturier; Hélène Pacquement; Giao Vu-Bezin; Brice Fresneau; Delphine Berchery; Stephanie Bolle; Ibrahima Diallo; Nadia Haddy; Florent de Vathaire

    PURPOSE Between 10% and 20% of childhood cancer survivors (CCS) experience impaired growth, leading to small adult height (SAH). Our study aimed to quantify risk factors for SAH or growth hormone deficiency among CCS.METHODS The French CCS Study holds data on 7,670 cancer survivors treated before 2001. We analyzed self-administered questionnaire data from 2,965 CCS with clinical, chemo/radiotherapy

    更新日期:2020-03-21
  • Increased Risk of Cardiovascular Sequelae in Survivors of Male Germ Cell Cancer
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-18
    Suparna C. Clasen; Chunkit Fung; Paul C. Dinh Jr; Lois B. Travis

    Studies in the United States1 and Europe2-6 have shown that both early and late cardiovascular effects are associated with platinum-based therapies. In their recent publication, Lauritsen et al2 undertake an epidemiologic survey to assess early and long-term cardiovascular effects in male survivors of germ cell cancer (GCC) compared with age-matched controls using data from the Danish National Registry

    更新日期:2020-03-19
  • Reply to S. Clasen et al
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-18
    Jakob Lauritsen; Mikkel Bandak; Michael Kreiberg; Thomas Wagner; Maria G.G. Kier; Christian Dehlendorff; Gedske Daugaard

    Clasen et al1 have commented in a letter on our study of cardiovascular disease after treatment of germ cell cancer. The risk of myocardial infarction during and shortly after treatment with bleomycin, etoposide, and cisplatin (BEP) is less than 1%.1,2 Compared with the devastating consequences of progressive disease, this may be an acceptable and possibly unavoidable acute adverse effect of treatment

    更新日期:2020-03-19
  • Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-17
    Jayesh Desai; Hui Gan; Catherine Barrow; Michael Jameson; Victoria Atkinson; Andrew Haydon; Michael Millward; Stephen Begbie; Michael Brown; Ben Markman; William Patterson; Andrew Hill; Lisa Horvath; Adnan Nagrial; Gary Richardson; Christopher Jackson; Michael Friedlander; Phillip Parente; Ben Tran; Lai Wang; Yunxin Chen; Zhiyu Tang; Wendy Huang; John Wu; Dewan Zeng; Lusong Luo; Benjamin Solomon

    PURPOSE Lifirafenib is an investigational, reversible inhibitor of B-RAFV600E, wild-type A-RAF, B-RAF, C-RAF, and EGFR. This first-in-human, phase I, dose-escalation/dose-expansion study evaluated the safety, tolerability, and efficacy of lifirafenib in patients with B-RAF– or K-RAS/N-RAS–mutated solid tumors.METHODS During dose escalation, adult patients with histologically/cytologically confirmed

    更新日期:2020-03-19
  • Models of Palliative Care Delivery for Patients With Cancer.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    David Hui,Eduardo Bruera

    Palliative care has evolved over the past five decades as an interprofessional specialty to improve quality of life and quality of care for patients with cancer and their families. Existing evidence supports that timely involvement of specialist palliative care teams can enhance the care delivered by oncology teams. This review provides a state-of-the-science synopsis of the literature that supports

    更新日期:2020-03-19
  • Patient-Clinician Communication Issues in Palliative Care for Patients With Advanced Cancer.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    Anthony L Back

    The delivery of palliative care to patients with advanced cancer and their families, whether done by oncology clinicians or palliative care clinicians, requires patient-centered communication. Excellent communication can introduce patients and families to palliative care in a nonthreatening way, build patient trust, enable symptom control, strengthen coping, and guide decision making. This review covers

    更新日期:2020-03-19
  • Prognostic Awareness in Adult Oncology and Palliative Care.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    Phyllis N Butow,Josephine M Clayton,Ronald M Epstein

    Communicating prognosis clearly and empathically can foster accurate prognostic awareness in patients with advanced cancer and their family members. Whereas patients and doctors desire clear prognostic communication, it presents many challenges in oncologic and palliative care settings. Patients with advanced cancer often have poor prognostic awareness as a result of deficiencies in doctor communication

    更新日期:2020-03-19
  • Psychological Interventions for Patients With Advanced Disease: Implications for Oncology and Palliative Care.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    Gary Rodin,Ekaterina An,Joanna Shnall,Carmine Malfitano

    A growing body of research demonstrates the feasibility and efficacy of psychological interventions for adult patients with advanced cancer. Findings from quantitative studies of psychotherapeutic interventions with primary psychological outcomes for such patients are reviewed here and recommendations for best practice are made. We consider these interventions according to three broad phases in which

    更新日期:2020-03-19
  • Palliative Care and the Management of Common Distressing Symptoms in Advanced Cancer: Pain, Breathlessness, Nausea and Vomiting, and Fatigue.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    Lesley A Henson,Matthew Maddocks,Catherine Evans,Martin Davidson,Stephanie Hicks,Irene J Higginson

    Good symptom management in oncology is associated with improved patient and family quality of life, greater treatment compliance, and may even offer survival advantages. With population growth and aging, the proportion of patients with multiple symptoms-both related and unrelated to their cancer-is anticipated to increase, supporting calls for a more routine and integrated approach to symptom management

    更新日期:2020-03-19
  • Understanding and Addressing the Role of Coping in Palliative Care for Patients With Advanced Cancer.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    Joseph A Greer,Allison J Applebaum,Juliet C Jacobsen,Jennifer S Temel,Vicki A Jackson

    Advanced cancer, with its considerable physical symptoms and psychosocial burdens, represents an existential threat and major stressor to patients and their caregivers. In response to such stress, patients and their caregivers use a variety of strategies to manage the disease and related symptoms, such as problem-focused, emotion-focused, meaning-focused, and spiritual/religious coping. The use of

    更新日期:2020-03-19
  • Palliative Care for Family Caregivers.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    Sorayya Alam,Breffni Hannon,Camilla Zimmermann

    Family caregivers provide substantial care for patients with advanced cancer, while suffering from hidden morbidity and unmet needs. The objectives of this review were to examine risk factors associated with caregiving for patients with advanced cancer, evaluate the evidence for pertinent interventions, and provide a practical framework for palliative care of caregivers in oncology settings. We reviewed

    更新日期:2020-03-19
  • Role of Hospice Care at the End of Life for People With Cancer.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    David C Currow,Meera R Agar,Jane L Phillips

    Patient-defined factors that are important at the end of life include being physically independent for as long as possible, good symptom control, and spending quality time with friends and family. Hospice care adds to the quality of care and these patient-centered priorities for people with cancer and their families in the last weeks and days of life. Evidence from large observational studies demonstrate

    更新日期:2020-03-19
  • Palliative and End-of-Life Care for Patients With Hematologic Malignancies.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    Areej El-Jawahri,Ashley M Nelson,Tamryn F Gray,Stephanie J Lee,Thomas W LeBlanc

    Hematologic malignancies are a heterogeneous group of diseases with unique illness trajectories, treatment paradigms, and potential for curability, which affect patients' palliative and end-of-life care needs. Patients with hematologic malignancies endure immense physical and psychological symptoms because of both their illness and often intensive treatments that result in significant toxicities and

    更新日期:2020-03-19
  • Pediatric Palliative Care in Oncology.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    Jennifer Snaman,Sarah McCarthy,Lori Wiener,Joanne Wolfe

    Pediatric palliative care aims to alleviate suffering and improve the quality of life of children with serious disease and increase support for their parents and other family members. Integration of palliative care into the routine care of children, adolescents, and young adults with cancer has resulted in improved outcomes in patients and their families. The field of pediatric palliative oncology-encompassing

    更新日期:2020-03-19
  • Forging a New Frontier: Providing Palliative Care to People With Cancer in Rural and Remote Areas.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    Marie Bakitas,Kristen Allen Watts,Emily Malone,J Nicholas Dionne-Odom,Susan McCammon,Richard Taylor,Rodney Tucker,Ronit Elk

    Mounting evidence supports oncology organizations' recommendations of early palliative care as a cancer care best practice for patients with advanced cancer and/or high symptom burden. However, few trials on which these best practices are based have included rural and remote community-based oncology care. Therefore, little is known about whether early palliative care models are applicable in these

    更新日期:2020-03-19
  • Disparities in Palliative Care in Patients With Cancer.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    Jennifer J Griggs

    In the United States, racial and ethnic minorities and people with lower socioeconomic status (SES) face structural, health system, and interpersonal barriers to optimal health care, including palliative care. Much of the available data on palliative care in racial and ethnic minorities and people with lower SES have identified disparities according to race, ethnicity, and SES. Limitations to understanding

    更新日期:2020-03-19
  • Economics of Palliative Care for Cancer: Interpreting Current Evidence, Mapping Future Priorities for Research.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    Peter May,Charles Normand,R Sean Morrison

    The National Cancer Institute estimates that $154 billion will be spent on care for people with cancer in 2019, distributed across the year after diagnosis (31%), the final year of life (31%), and continuing care between those two (38%). Projections of future costs estimate persistent growth in care expenditures. Early research studies on the economics of palliative care have reported a general pattern

    更新日期:2020-03-19
  • Dissemination and Implementation of Palliative Care in Oncology.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    Betty R Ferrell,Vincent Chung,Marianna Koczywas,Thomas J Smith

    Palliative care began in academic centers with specialty consultation services, and its value to patients, families, and health systems has been evident. The demand for palliative care to be integrated throughout the cancer trajectory, combined with a limited palliative care workforce, means that new models of care are needed. This review discusses evidence regarding the need for integration of palliative

    更新日期:2020-03-19
  • Standards, Guidelines, and Quality Measures for Successful Specialty Palliative Care Integration Into Oncology: Current Approaches and Future Directions.
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-02-05
    Arif H Kamal,Claudia Bausewein,David J Casarett,David C Currow,Deborah J Dudgeon,Irene J Higginson

    Although robust evidence demonstrates that specialty palliative care integrated into oncology care improves patient and health system outcomes, few clinicians are familiar with the standards, guidelines, and quality measures related to integration. These types of guidance outline principles of best practice and provide a framework for assessing the fidelity of their implementation. Significant advances

    更新日期:2020-03-19
  • Targets and Antibody Formats for Immunotherapy of Neuroblastoma
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-13
    Jeong A. Park; Nai-Kong V. Cheung

    Neuroblastoma (NB) is a malignant embryonal tumor of the sympathetic nervous system that is most commonly diagnosed in the abdomen, often presenting with signs and symptoms of metastatic spread. Three decades ago, high-risk NB metastatic to bone and bone marrow in children was not curable. Today, with multimodality treatment, 50% of these patients will survive, but most suffer from debilitating treatment-related

    更新日期:2020-03-16
  • Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-13
    Daniel V.T. Catenacci; Drew Rasco; Jeeyun Lee; Sun Young Rha; Keun-Wook Lee; Yung Jue Bang; Johanna Bendell; Peter Enzinger; Neyssa Marina; Hong Xiang; Wei Deng; Janine Powers; Zev A. Wainberg

    PURPOSE To evaluate the safety, pharmacokinetics, and preliminary activity of bemarituzumab in patients with FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma (GEA).PATIENTS AND METHODS FPA144-001 was a phase I, open-label, multicenter trial consisting of the following 3 parts: part 1a involved dose escalation in patients with recurrent solid tumors at doses ranging from 0

    更新日期:2020-03-16
  • Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-13
    Andrea Maurichi; Rosalba Miceli; Hanna Eriksson; Julia Newton-Bishop; Jérémie Nsengimana; May Chan,PGD; Andrew J. Hayes; Kara Heelan; David Adams; Roberto Patuzzo; Francesco Barretta; Gianfranco Gallino; Catherine Harwood; Daniele Bergamaschi; Dorothy Bennett; Konstantinos Lasithiotakis; Paola Ghiorzo; Bruna Dalmasso; Ausilia Manganoni; Francesca Consoli; Ilaria Mattavelli; Consuelo Barbieri; Andrea

    PURPOSE Thin melanomas (T1; ≤ 1 mm) constitute 70% of newly diagnosed cutaneous melanomas. Regional node metastasis determined by sentinel node biopsy (SNB) is an important prognostic factor for T1 melanoma. However, current melanoma guidelines do not provide clear indications on when to perform SNB in T1 disease and stress an individualized approach to SNB that considers all clinicopathologic risk

    更新日期:2020-03-16
  • Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR)
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-13
    Jean-François Delattre; Romain Cohen; Julie Henriques; Antoine Falcoz; Jean-François Emile; Serge Fratte; Benoist Chibaudel; Jérôme Dauba; Olivier Dupuis; Yves Bécouarn; Frédéric Bibeau; Julien Taieb; Christophe Louvet; Dewi Vernerey; Thierry André; Magali Svrcek

    PURPOSE Tumor deposits (TDs) seem to affect the prognosis of patients with colon cancer (CC). In the seventh edition of the American Joint Committee on Cancer TNM staging system for CC, the presence of TDs is only considered in the absence of lymph node metastases (LNMs). In the era of personalized duration of histopathologic criteria-based adjuvant therapy, this could potentially lead to a decrease

    更新日期:2020-03-16
  • Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-13
    Vicky Makker; Matthew H. Taylor; Carol Aghajanian; Ana Oaknin; James Mier; Allen L. Cohn; Margarita Romeo; Raquel Bratos; Marcia S. Brose; Christopher DiSimone; Mark Messing; Daniel E. Stepan; Corina E. Dutcus; Jane Wu; Emmett V. Schmidt; Robert Orlowski; Pallavi Sachdev; Robert Shumaker; Antonio Casado Herraez

    PURPOSE Patients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus pembrolizumab in an ongoing phase Ib/II study of selected solid tumors.METHODS Patients took lenvatinib 20 mg once daily orally plus pembrolizumab 200 mg intravenously once every 3 weeks

    更新日期:2020-03-16
  • Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-11
    Arnoud J. Templeton; Christopher M. Booth; Ian F. Tannock

    When physicians inform patients about the likely outcome of a recommended treatment, most will review evidence from clinical trials that evaluated that treatment and describe the likely benefits and toxicities, as reported in the trials. The probabilities of beneficial outcome and of toxicity written in consent forms approved by institutional review boards likewise are based on findings of pivotal

    更新日期:2020-03-12
  • Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-11
    Steven H. Lin; Brian P. Hobbs; Vivek Verma; Rebecca S. Tidwell; Grace L. Smith; Xiudong Lei; Erin M. Corsini; Isabel Mok; Xiong Wei; Luyang Yao; Xin Wang; Ritsuko U. Komaki; Joe Y. Chang; Stephen G. Chun; Melenda D. Jeter; Stephen G. Swisher; Jaffer A. Ajani; Mariela Blum-Murphy; Ara A. Vaporciyan; Reza J. Mehran; Albert C. Koong; Saumil J. Gandhi; Wayne L. Hofstetter; Theodore S. Hong; Thomas F. Delaney;

    PURPOSE Whether dosimetric advantages of proton beam therapy (PBT) translate to improved clinical outcomes compared with intensity-modulated radiation therapy (IMRT) remains unclear. This randomized trial compared total toxicity burden (TTB) and progression-free survival (PFS) between these modalities for esophageal cancer.METHODS This phase IIB trial randomly assigned patients to PBT or IMRT (50.4

    更新日期:2020-03-12
  • Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-11
    Noa Biran; David H. Vesole; Michele L. Donato; Andrew Ip; Gurbakhash Kaur; Stuart Goldberg; David S. Siegel

    In a recent study by Lonial et al1 in the Journal of Clinical Oncology, it was concluded that among patients with high-risk smoldering multiple myeloma (SMM), early intervention with lenalidomide (len) could delay progression to symptomatic multiple myeloma (MM). It was proposed by the authors that these data, together with the results of the randomized Spanish trial,2 represent a new standard of care

    更新日期:2020-03-12
  • Reply to N. Biran et al
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-11
    Sagar Lonial; Madhav V. Dhodapkar; S. Vincent Rajkumar

    We thank Biran et al1 for commenting on our study. We reported on the largest randomized trial conducted in smoldering multiple myeloma (SMM), and our recommendations are based on our trial results2 as well as those previously reported by the Spanish group.3 Collectively, the two trials clearly show that we can prolong time to end-organ damage with lenalidomide-based therapy. Although some patients

    更新日期:2020-03-12
  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-09
    Shirish Gadgeel; Delvys Rodríguez-Abreu; Giovanna Speranza; Emilio Esteban; Enriqueta Felip; Manuel Dómine; Rina Hui; Maximilian J. Hochmair; Philip Clingan; Steven F. Powell; Susanna Yee-Shan Cheng; Helge G. Bischoff; Nir Peled; Francesco Grossi; Ross R. Jennens; Martin Reck; Edward B. Garon; Silvia Novello; Belén Rubio-Viqueira; Michael Boyer; Takayasu Kurata; Jhanelle E. Gray; Jing Yang; Tuba Bas;

    PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. We report an updated analysis from KEYNOTE-189 (ClinicalTrials

    更新日期:2020-03-10
  • Could the Women’s Health Initiative Breathe New Life Into Breast Cancer Prevention?
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-09
    Jennifer A. Ligibel

    Breast cancer is the most commonly diagnosed noncutaneous malignancy in US women, with an anticipated 276,480 cases in 2020.1 Despite recent advances in detection and treatment, > 41,000 deaths are attributable to the disease each year.1,2 Selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) have been shown to significantly reduce the risk of breast cancer in at-risk women

    更新日期:2020-03-10
  • Adherence to Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors: A Childhood Cancer Survivor Study
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-06
    Adam P. Yan; Yan Chen; Tara O. Henderson; Kevin C. Oeffinger; Melissa M. Hudson; Todd M. Gibson; Joseph P. Neglia; Wendy M. Leisenring; Kirsten K. Ness; Jennifer S. Ford; Leslie L. Robison; Gregory T. Armstrong; Yutaka Yasui; Paul C. Nathan

    PURPOSE To evaluate childhood cancer survivors’ adherence to surveillance protocols for late effects of treatment and to determine the factors affecting adherence.METHODS Between 2014 and 2016, 11,337 survivors and 2,146 siblings in the Childhood Cancer Survivor Study completed a survey ascertaining adherence to Children’s Oncology Group (COG) guidelines for survivors at high risk for second malignant

    更新日期:2020-03-09
  • Alternative Donor Transplantation for Lymphoid Malignancies: How Far We Have Come
    J. Clin. Oncol. (IF 28.245) Pub Date : 2020-03-06
    Koen W. van Besien; Nina Orfali

    The rapid pace of drug discovery combined with advances in biology and diagnostics has revolutionized the treatment of lymphoma, epitomized by the approval of chimeric antigen receptor T-cell therapy for patients with large B-cell lymphoma. Yet allogeneic transplantation continues to play an important role for patients who experience treatment failure with standard therapies, and in the United States

    更新日期:2020-03-09
Contents have been reproduced by permission of the publishers.
导出
全部期刊列表>>
宅家赢大奖
向世界展示您的会议墙报和演示文稿
全球疫情及响应:BMC Medicine专题征稿
新版X-MOL期刊搜索和高级搜索功能介绍
化学材料学全球高引用
ACS材料视界
x-mol收录
自然科研论文编辑服务
南方科技大学
南方科技大学
西湖大学
中国科学院长春应化所于聪-4-8
复旦大学
课题组网站
X-MOL
深圳大学二维材料实验室张晗
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug